247 related articles for article (PubMed ID: 38313232)
1. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
[TBL] [Abstract][Full Text] [Related]
2. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
3. Circulating miRNAs associated with nonalcoholic fatty liver disease.
Atic AI; Thiele M; Munk A; Dalgaard LT
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat.
Quintás G; Caiment F; Rienda I; Pérez-Rojas J; Pareja E; Castell JV; Jover R
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012565
[TBL] [Abstract][Full Text] [Related]
5. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
[TBL] [Abstract][Full Text] [Related]
6. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
[TBL] [Abstract][Full Text] [Related]
8. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
9. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
10. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
Zheng C; Nie H; Pan M; Fan W; Pi D; Liang Z; Liu D; Wang F; Yang Q; Zhang Y
J Ethnopharmacol; 2024 Jan; 318(Pt A):116967. PubMed ID: 37506783
[TBL] [Abstract][Full Text] [Related]
11. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.
Soronen J; Yki-Järvinen H; Zhou Y; Sädevirta S; Sarin AP; Leivonen M; Sevastianova K; Perttilä J; Laurila PP; Sigruener A; Schmitz G; Olkkonen VM
Physiol Rep; 2016 Jan; 4(1):. PubMed ID: 26733244
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis.
Shen Y; Cheng L; Xu M; Wang W; Wan Z; Xiong H; Guo W; Cai M; Xu F
Metabolism; 2023 Sep; 146():155657. PubMed ID: 37422021
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway.
Cai Q; Chen F; Xu F; Wang K; Zhang K; Li G; Chen J; Deng H; He Q
Metabolism; 2020 Mar; 104():154140. PubMed ID: 31926204
[TBL] [Abstract][Full Text] [Related]
16. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
[TBL] [Abstract][Full Text] [Related]
17. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.
Sharma H; Estep M; Birerdinc A; Afendy A; Moazzez A; Elariny H; Goodman Z; Chandhoke V; Baranova A; Younossi ZM
J Gastroenterol Hepatol; 2013 Aug; 28(8):1410-5. PubMed ID: 23663110
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs Are Associated With Metabolic Markers in Adolescents With Hepatosteatosis.
Lin H; Mercer KE; Ou X; Mansfield K; Buchmann R; Børsheim E; Tas E
Front Endocrinol (Lausanne); 2022; 13():856973. PubMed ID: 35498403
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
[TBL] [Abstract][Full Text] [Related]
20. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
